Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
277 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07711184 | A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer | recruiting | Phase 1 | 320 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT07136142 | A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06568094 | A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06057610 | A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer | active not recruiting | Phase 3 | 868 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07556822 | Phase I Study of HRS-3005 in B-cell Malignancies | recruiting | Phase 1 | 190 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07806058 | An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 140 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07796763 | A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2(HORIZON-CRC221) | not yet recruiting | Phase 2 | 48 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05942001 | Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | recruiting | Phase 1 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06598735 | A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 290 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07790380 | FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. | not yet recruiting | Phase 3 | 480 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07610148 | A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants | active not recruiting | Phase 1 | 21 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03980054 | A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | active not recruiting | Phase 3 | 2,135 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05814354 | SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial | active not recruiting | Phase 3 | 551 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06516926 | SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors | terminated | Phase 2 | 11 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07196774 | A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer | active not recruiting | Phase 3 | 740 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06413745 | Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer | active not recruiting | Phase 2 | 59 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06555068 | A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 528 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07232875 | HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer | recruiting | Phase 3 | 588 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06126640 | A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy | active not recruiting | Phase 3 | 1,615 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07140393 | A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor | recruiting | Phase 1 / Phase 2 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06091748 | Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors | completed | Phase 3 | 69 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06974929 | A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer | recruiting | Phase 1 / Phase 2 | 80 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04621669 | Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride | completed | Phase 1 | 36 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05363800 | Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma | active not recruiting | Phase 1 | 74 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06710990 | Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer | completed | Phase 1 | 17 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05277168 | A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | recruiting | Phase 1 / Phase 2 | 83 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT05884255 | An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. | recruiting | Phase 3 | 220 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07241416 | A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer | recruiting | Phase 3 | 206 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT07497386 | A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer | recruiting | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT07407283 | A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05482568 | A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 324 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06828354 | A Study of SHR-A1811 in Subjects With Ovarian Cancer | recruiting | Phase 3 | 300 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07380334 | A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07241767 | A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer | recruiting | Phase 2 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05009290 | A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy | terminated | Phase 3 | 391 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07446153 | A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects | recruiting | Phase 1 / Phase 2 | 282 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05318833 | A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors | completed | Phase 1 | 38 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05781048 | A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07189949 | A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications | recruiting | Phase 1 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03083041 | A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 210 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07230106 | A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer | recruiting | Phase 2 | 218 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03463876 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) | completed | Phase 2 | 190 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04513223 | A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors | completed | Phase 1 | 101 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07311694 | A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 3 | 370 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT03092895 | A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC | completed | Phase 2 | 157 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06430437 | A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations | recruiting | Phase 3 | 300 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | recruiting | Phase 3 | 550 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06122389 | SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma | recruiting | Phase 3 | 130 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04639180 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | active not recruiting | Phase 3 | 687 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04447118 | Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy(PYRAMID-1) | completed | Phase 3 | 151 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 19, 2025 | clinicaltrials |
Data updated 5 days agoSource updated unknownsource: clinicaltrials